<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Equasens Sa — News on 6ix</title>
<link>https://6ix.com/company/equasens-sa</link>
<description>Latest news and press releases for Equasens Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/equasens-sa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d5310dbeedb30cb6f6d3af.webp</url>
<title>Equasens Sa</title>
<link>https://6ix.com/company/equasens-sa</link>
</image>
<item>
<title>2025 annual results: Equasens reports a solid performance across all financial indicators</title>
<link>https://6ix.com/company/equasens-sa/news/2025-annual-results-equasens-reports-a-solid-performance-across-all-financial-indicators-2</link>
<guid isPermaLink="true">https://6ix.com/company/equasens-sa/news/2025-annual-results-equasens-reports-a-solid-performance-across-all-financial-indicators-2</guid>
<pubDate>Mon, 30 Mar 2026 06:00:00 GMT</pubDate>
<description>Villers-lès-Nancy, 30 March 2026 - 08:00 (CEST) PRESS RELEASE 2025 annual resultsEquasens reports a solid performanceacross all financial indicators FY 2025 revenue of €236.5 million (+9.1%): continued strong performance driven by a portfolio of innovative solutions for healthcare professionals and providers Annual Recurring Revenue (ARR) up sharply: €108.0 million at December 31, 2025, representing 8.8% growth versus 2024 EBITDA of €66.7 million (+9.1%), highlighting effective cost control in a</description>
</item>
<item>
<title>Strong commercial performance in 2025: Annual Recurring Revenue (ARR) of €108.0m (+8.8% as reported on 31 December 2025) and full-year revenue of €236.5m (+9.1% as reported)</title>
<link>https://6ix.com/company/equasens-sa/news/strong-commercial-performance-in-2025-annual-recurring-revenue-arr-of-euro1080m-88percent-as-reported-on-31-december-2025-and-full-year-revenue-of-euro2365m-91percent-as-reported-1</link>
<guid isPermaLink="true">https://6ix.com/company/equasens-sa/news/strong-commercial-performance-in-2025-annual-recurring-revenue-arr-of-euro1080m-88percent-as-reported-on-31-december-2025-and-full-year-revenue-of-euro2365m-91percent-as-reported-1</guid>
<pubDate>Thu, 05 Feb 2026 17:02:00 GMT</pubDate>
<description>Villers-lès-Nancy, 05 February 2026 - 6:00 PM (CET) PRESS RELEASE Strong commercial performance in 2025: Annual Recurring Revenue (ARR) of €108.0m (+8.8% as reported on 31 December 2025) and full-year revenue of €236.5m (+9.1% as reported) First disclosure of Annual Recurring Revenue (ARR), reaching €108.0m at 31 December 2025, up a robust 8.8% year on yearGrowth driven by all business divisions, with particularly strong momentum in the second half and in Q4 2025, up 10.8% and 9.7% respectively</description>
</item>
<item>
<title>EQUASENS ACCELERATES ITS DIGITAL TRAINING STRATEGY FOR HEALTHCARE PROFESSIONALS WITH THE ACQUISITION OF EREVO, A LEADING PURE-PLAY E-LEARNING PROVIDER</title>
<link>https://6ix.com/company/equasens-sa/news/equasens-accelerates-its-digital-training-strategy-for-healthcare-professionals-with-the-acquisition-of-erevo-a-leading-pure-play-e-learning-provider-1</link>
<guid isPermaLink="true">https://6ix.com/company/equasens-sa/news/equasens-accelerates-its-digital-training-strategy-for-healthcare-professionals-with-the-acquisition-of-erevo-a-leading-pure-play-e-learning-provider-1</guid>
<pubDate>Mon, 05 Jan 2026 07:00:00 GMT</pubDate>
<description>EQUASENS ACCELERATES ITS DIGITAL TRAINING STRATEGY FOR HEALTHCARE PROFESSIONALS WITH THE ACQUISITION OF EREVO, A LEADING PURE-PLAY E-LEARNING PROVIDER Acquisition of a controlling 80% stake in Erevo, which is expected to generate revenue of €7.4 million in 2025, with profitability in line with the Group’s performance Expansion of Equasens’ healthcare-professional training offering, alongside Atoopharm, to deliver best-in-class industry standardsFurther strengthening of Equasens’ services portfol</description>
</item>
<item>
<title>EQUASENS ANNOUNCES ITS 2026 FINANCIAL CALENDAR</title>
<link>https://6ix.com/company/equasens-sa/news/equasens-announces-its-2026-financial-calendar-1</link>
<guid isPermaLink="true">https://6ix.com/company/equasens-sa/news/equasens-announces-its-2026-financial-calendar-1</guid>
<pubDate>Wed, 10 Dec 2025 17:00:00 GMT</pubDate>
<description>Villers-lès-Nancy, December 10, 2026, 6:00 p.m. CET – Equasens (ISIN: FR 0012882389 – Ticker: EQS), a leader in digital solutions for healthcare professionals, announces its financial calendar for the 2026 financial year. EventsDates2025 annual revenueFebruary 5, 2026 (after market close)2025 annual resultsMarch 30, 2026 (before market opens)2026 Q1 revenueApril 29, 2026 (after market close)Annual General MeetingJune 25, 20262026 Half-year revenueJuly 30, 2026 (after market close)2026 Half-year</description>
</item>
<item>
<title>Equasens: Q3 2025 revenue</title>
<link>https://6ix.com/company/equasens-sa/news/equasens-q3-2025-revenue-1</link>
<guid isPermaLink="true">https://6ix.com/company/equasens-sa/news/equasens-q3-2025-revenue-1</guid>
<pubDate>Wed, 05 Nov 2025 17:00:00 GMT</pubDate>
<description>Villers-lès-Nancy, 5 November 2025 - 6:00 PM (CET) PRESS RELEASE Revenue at 30 September 2025: €172.2m+8.9% on a reported basis and +7.3% like-for-like Group revenue at 09/30/2025 (€m)2024Reported basis 2025Reported basisChange /Reported basisof which external growthLike-for-like change(organic growth)Q153.357.03.76.9%0.53.25.9%Q254.758.94.37.8%0.53.86.9%Q3*50.256.26.112.1%1.44.79.4%Total158.2172.214.08.9%2.411.67.3% * Unaudited At September 30, 2025, the Equasens Group (Euronext Paris™ - Compar</description>
</item>
<item>
<title>Equasens: 2025 half-year results</title>
<link>https://6ix.com/company/equasens-sa/news/equasens-2025-half-year-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/equasens-sa/news/equasens-2025-half-year-results-1</guid>
<pubDate>Fri, 26 Sep 2025 16:00:00 GMT</pubDate>
<description>Villers-lès-Nancy, 26 September 2025 - 6:00 PM (CET) PRESS RELEASE 2025 half-year results Revenue: €116.0m (+7.4% reported and +6.4% like-for-like)Recurring EBITDA: €29.8m (+5.5%)Current Operating Profit €21.1m (+1.2%) Net Profit: €18.1m (+0.3%)Net Financial Surplus : €98.8m (+€19.2m / 31-12-2024) H1 2025 RESULTS(M€)2024Reported basis2025Reported basisChange / Reported basisRevenue108.0116.08.07.4%Recurring EBITDA28.229.81.55.5%Recurring EBITDA / Sales26.1%25.7% Current operating profit20.921.10</description>
</item>
<item>
<title>Equasens: H1 revenue at 30 June 2025: €116.0m</title>
<link>https://6ix.com/company/equasens-sa/news/equasens-h1-revenue-at-30-june-2025-euro1160m-1</link>
<guid isPermaLink="true">https://6ix.com/company/equasens-sa/news/equasens-h1-revenue-at-30-june-2025-euro1160m-1</guid>
<pubDate>Thu, 31 Jul 2025 16:00:00 GMT</pubDate>
<description>Villers-lès-Nancy (France), 31 July 2025 - 6:00 PM (CET) PRESS RELEASE H1 revenue at 30 June 2025: €116.0m+7.4% on a reported basis and +6.4% like-for-like H1 2025 Group revenue (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growth)Q153.357.03.76.9%0.53.25.9%Q254.758.94.37.8%0.53.86.9%Total108.0116.08.07.4%1.16.96.4%H1 2025 revenue / Division (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthL</description>
</item>
<item>
<title>Equasens: Appointment at the head of the Pharmagest Division</title>
<link>https://6ix.com/company/equasens-sa/news/equasens-appointment-at-the-head-of-the-pharmagest-division-1</link>
<guid isPermaLink="true">https://6ix.com/company/equasens-sa/news/equasens-appointment-at-the-head-of-the-pharmagest-division-1</guid>
<pubDate>Thu, 03 Jul 2025 16:00:00 GMT</pubDate>
<description>Villers-lès-Nancy (France), July 03, 2025 – 06 :00pm (CET) Press Release Equasens announces the departure of Damien VALICON, as Deputy Chief Executive Officer and Director of the Pharmagest Division He will be replaced by François-Pierre MARQUIER as Director of the Pharmagest Division. *** Equasens Group (Euronext Paris™ - Compartment B - FR 0012882389 –$EQS), announces the departure of Damien VALICON, who held the position of Deputy Chief Executive Officer and Director of the Pharmagest Divisio</description>
</item>
<item>
<title>Equasens: General meeting - Results of the votes</title>
<link>https://6ix.com/company/equasens-sa/news/equasens-general-meeting-results-of-the-votes-1</link>
<guid isPermaLink="true">https://6ix.com/company/equasens-sa/news/equasens-general-meeting-results-of-the-votes-1</guid>
<pubDate>Tue, 01 Jul 2025 17:00:00 GMT</pubDate>
<description>Villers-lès-Nancy, 1st July 2025 – 07:00 p.m. (CET) PRESS RELEASE RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING OF 25 JUNE 2025 Number of shares comprising the share capital: 15,174,125 Number of shares with voting rights: 14,830,415 Number of shares with voting rights possessed by shareholders presents or represented or having voted by mail: 13,173,125 That means a quorum of 88.83% of the 14,830,415 shares with voting rights: the Ordinary Annual</description>
</item>
<item>
<title>Equasens: acquisition of DIS and RESURGENCES BUSINESSES</title>
<link>https://6ix.com/company/equasens-sa/news/equasens-acquisition-of-dis-and-resurgences-businesses-1</link>
<guid isPermaLink="true">https://6ix.com/company/equasens-sa/news/equasens-acquisition-of-dis-and-resurgences-businesses-1</guid>
<pubDate>Mon, 30 Jun 2025 16:00:00 GMT</pubDate>
<description>Villers-lès-Nancy (France), 30 June 2025 - 06:00 PM (CET) PRESS RELEASE EQUASENS ACQUIRES DIS AND RESURGENCES BUSINESSES, STRENGTHENING ITS POSITION IN THE MARKET OF SOFTWARE SOLUTIONS FOR HEALTHCARE ESTABLISHMENTS. Strengthening the position of a leading provider of software solutions for hospitals and the medical-social sector Transaction finalised: acquisition of Novaprove, publisher of ResUrgences software and the DIS business assets, (GESDIS, FACDIS, ARCADIS ranges)Acquisition scope: more t</description>
</item>
<item>
<title>Equasens: availability of AGM preparatory materials</title>
<link>https://6ix.com/company/equasens-sa/news/equasens-availability-of-agm-preparatory-materials-1</link>
<guid isPermaLink="true">https://6ix.com/company/equasens-sa/news/equasens-availability-of-agm-preparatory-materials-1</guid>
<pubDate>Fri, 06 Jun 2025 16:00:00 GMT</pubDate>
<description>Villers-lès-Nancy, 6 June 2025 - 6:00 p.m. (CET) PRESS RELEASE ANNUAL ORDINARY GENERAL MEETING MEETING NOTICE ON-LINE AVAILABILITY OF MEETING MATERIALS WEBCAST LIVE EQUASENS hereby provides notice to shareholders of the Annual Ordinary General Meeting to be held on Wednesday, June 25, 2025 at 5.30 pm at the Company’s registered office located in Villers-lès-Nancy (Technopôle de Nancy-Brabois - 5 Allée de Saint Cloud). The original French language version of the agenda and the resolutions submitt</description>
</item>
<item>
<title>Equasens: Q1 revenue at 31 March 2025</title>
<link>https://6ix.com/company/equasens-sa/news/equasens-q1-revenue-at-31-march-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/equasens-sa/news/equasens-q1-revenue-at-31-march-2025-1</guid>
<pubDate>Mon, 12 May 2025 16:00:00 GMT</pubDate>
<description>Villers-lès-Nancy, 12 May 2025 - 6:00 PM (CET) PRESS RELEASE Q1 revenue at 31 March 2025: €57.0m+ 6.9% growth on a reported basis and + 5.9% like-for-like Q1 2025 REVENUE (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growth)Equasens Group 53.357.03.76.9%0.53.25.9%Q1 2025 revenue / Division (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growth)Pharmagest39.842.0</description>
</item>
<item>
<title>Equasens: EXCLUSIVE NEGOTIATIONS INITIATED WITH A FRENCH SOFTWARE EDITOR</title>
<link>https://6ix.com/company/equasens-sa/news/equasens-exclusive-negotiations-initiated-with-a-french-software-editor-1</link>
<guid isPermaLink="true">https://6ix.com/company/equasens-sa/news/equasens-exclusive-negotiations-initiated-with-a-french-software-editor-1</guid>
<pubDate>Wed, 30 Apr 2025 06:00:00 GMT</pubDate>
<description>Villers-lès-Nancy, 30 April 2025 - 8:00 AM (CET) PRESS RELEASE EXCLUSIVE NEGOTIATIONS INITIATED WITH A FRENCH SOFTWARE EDITOR TO ACQUIRE TWO SOFTWARE PUBLISHING BUSINESSES OPERATING IN THE PUBLIC HEALTH SECTOR Project for a targeted acquisition in the public health sector: Acquisition of Novaprove, publisher of the ResUrgences software, Acquisition of the DIS business assets, Strategic reinforcement of Equasens Group's Axigate Link division in this market segment *** Equasens Group (Euronext Par</description>
</item>
</channel>
</rss>